The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
An anti-human interleukin 5 receptor (hIL-5R) humanized immunoglobulin G1 (IgG1) and an anti-CD20 chimeric IgG1 produced by rat hybridoma YB2/0 cell lines showed more than 50-fold higher antibody-dependent cellular cytotoxicity (ADCC) using purified human peripheral blood mononuclear cells as effector than those produced by Chinese hamster ovary (CHO) cell lines. Monosaccharide composition and oligosaccharide profiling analysis showed that low fucose (Fuc) content of complex-type oligosaccharides was characteristic in YB2/0-produced IgG1s compared with high Fuc content of CHO-produced IgG1s. YB2/0-produced anti-hIL-5R IgG1 was subjected to Lens culinaris aggulutin affinity column and fractionated based on the contents of Fuc. The lower Fuc IgG1 had higher ADCC than the IgG1 before separation. In contrast, the content of bisecting GlcNAc of the IgG1 affected ADCC much less than that of Fuc. In addition, the correlation between Gal and ADCC was not observed. When the combined effect of Fuc and bisecting GlcNAc was examined in anti-CD20 IgG1, only a severalfold increase of ADCC was observed by the addition of GlcNAc to highly fucosylated IgG1. Quantitative PCR analysis indicated that YB2/0 cells had lower expression level of FUT8 mRNA, which codes alpha1,6-fucosyltransferase, than CHO cells. Overexpression of FUT8 mRNA in YB2/0 cells led to an increase of fucosylated oligosaccharides and decrease of ADCC of the IgG1. These results indicate that the lack of fucosylation of IgG1 has the most critical role in enhancement of ADCC, although several reports have suggested the importance of Gal or bisecting GlcNAc and provide important information to produce the effective therapeutic antibody.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is ideal as increases in fucosylation have been correlated with decreased ADCC activity and decreased FcγRIIIa and FcγRIIb binding affinity. 40 , 41 , 42 , 43”
From Dynamic pH profiles drive higher cell‐specific and volumetric productivity (2026) · cites this paper as [42]
In the citing paper
“lower cell specific productivity has been shown to allow for more mature glycoforms, including G2F. 42”
From Dynamic pH profiles drive higher cell‐specific and volumetric productivity (2026) · cites this paper as [42]
In the citing paper
“Enriching the abundance of mAb N-glycoforms with β1,4-linked galactose (Gal) can also be desirable as it has been shown to enhance complement-dependent cytotoxicity (CDC), another mechanism for the selective depletion of tumour cells by Fc activation of the complement pathway [16–21].”
From Glycoengineering Chinese hamster ovary cells: a short history (2021) · cites this paper as [16]
In the citing paper
“The addition of bisecting β1,4-linked N-acetylglucosamine (GlcNAc) by endogenous or recombinant N-acetylglucosaminyltransferase III (GnT-III in YB2/0 and CHO cells respectively) or via in vitro glycan remodelling has also been linked to increased ADCC in IgGs, albeit to a lesser extent than afucosylation [15–17].”
From Glycoengineering Chinese hamster ovary cells: a short history (2021) · cites this paper as [16]
In the citing paper
“It was reported that afucosylated Fc domain glycans of human IgG1 could enhance the binding to FcγRIIIa subtype receptors of natural killer cells (Shields et al., 2002;Shinkawa et al., 2003;Niwa et al., 2005;Iida et al., 2006;Subedi and Barb, 2016).”
From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Shinkawa et al., 2003
Citations
Cites
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835
Deisenhofer, J. (1981) · PubMed · Cited by 1,422
Deisenhofer, J. (1981) · Biochemistry · doi:10.1021/bi00512a001 · Cited by 1,333
Parekh, R. B., Dwek, R. A., Sutton, B. J., Fernandes, D. L., Leung, A., Stanworth, D., Rademacher, T. W., Mizuochi, T., Taniguchi, T., Matsuta, K., et al. (1985) · Nature · doi:10.1038/316452a0 · Cited by 1,170
Umaña, P., Jean–Mairet, J., Moudry, R., Amstutz, H., & Bailey, J. E. (1999) · Nature Biotechnology · doi:10.1038/6179 · Cited by 764
Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies
Lewis, G. D., Figari, I., Fendly, B., Lee Wong, W., Carter, P., Gorman, C., & Shepard, H. M. (1993) · Cancer Immunology, Immunotherapy · doi:10.1007/bf01518520 · Cited by 498
Refined Structure of an Intact IgG2a Monoclonal Antibody,
Harris, L. J., Larson, S. B., Hasel, K. W., & McPherson, A. (1997) · Biochemistry · doi:10.1021/bi962514+ · Cited by 451
Crystallographic structure of an intact IgG1 monoclonal antibody 1 1Edited by I. A. Wilson
Harris, L. J., Skaletsky, E., & McPherson, A. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.1508 · Cited by 440
Research works printed but not linked: 2
- Rademacher, 1986, Biochem. Soc. Symp., 51, 131
- Kumpel, 1994, Hum. Antib. Hybrid., 5, 143
Cited by
Items 201–300 of 1,000
Impact of structural modifications of IgG antibodies on effector functions
Damelang, T., Brinkhaus, M., van Osch, T. L. J., Schuurman, J., Labrijn, A. F., Rispens, T., & Vidarsson, G. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1304365 · Cited by 123
Chung, S., Quarmby, V., Gao, X., Ying, Y., Lin, L., Reed, C., Fong, C., Lau, W., Qiu, Z. J., Shen, A., et al. (2012) · mAbs · doi:10.4161/mabs.19941 · Cited by 127
Kanda, Y., Imai, H., Kuni‐Kamochi, R., Mori, K., Inoue, M., Kitajima-Miyama, K., Okazaki, A., Iida, S., Shitara, K., & Satoh, M. (2007) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2007.04.025 · Cited by 131
Self-citationNaturally occurring glycan forms of human immunoglobulins G1 and G2
Flynn, G. C., Chen, X., Liu, D., Shah, B., & Zhang, Z. (2010) · Molecular Immunology · doi:10.1016/j.molimm.2010.04.006 · Cited by 135
Protein glycosylation in cancers and its potential therapeutic applications in neuroblastoma
Ho, W., Hsu, W., Huang, M., Kadomatsu, K., & Nakagawara, A. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0334-6 · Cited by 127
“The concept of this technology originated from the discovery that reducing or eliminating fucose from the oligosaccharides on the Fc domain significantly increased FcγRIIIa binding and dramatically enhanced ADCC by ~100-fold [121].”
Ito, A., Ishida, T., Yano, H., Inagaki, A., Suzuki, S., Sato, F., Takino, H., Mori, F., Ri, M., Kusumoto, S., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0632-0 · Cited by 143
“Accordingly, we have developed a next-generation chimeric anti-CCR4 mAb, KM2760, the Fc region of which is defucosylated [21], resulting in highly enhanced ADCC due to increased binding aYnity to the Fc receptor (Fc R) on eVector cells [10, 15].”
BackgroundNoda, K., Miyoshi, E., Gu, J., Gao, C., Nakahara, S., Kitada, T., Honke, K., Suzuki, K., Yoshihara, H., YOSHIKAWA, K., et al. (2003) · PubMed · Cited by 126
The future of antibodies as cancer drugs
Reichert, J. M., & Dhimolea, E. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.04.006 · Cited by 136
Core fucosylation of E‐cadherin enhances cell–cell adhesion in human colon carcinoma WiDr cells
Osumi, D., Takahashi, M., Miyoshi, E., Yokoe, S., Lee, S. H., Noda, K., Nakamori, S., Gu, J., Ikeda, Y., Kuroki, Y., et al. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01125.x · Cited by 124
Evaluating the impact of cell culture process parameters on monoclonal antibody N-glycosylation
Ivarsson, M., Villiger, T. K., Morbidelli, M., & Šoóš, M. (2014) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2014.08.026 · Cited by 152
Teylaert, B., Meurice, E., Bobowski, M., Harduin-Lepers, A., Gaucher, C., Fontayne, A., Jorieux, S., & Delannoy, P. (2011) · BMC Biotechnology · doi:10.1186/1472-6750-11-1 · Cited by 123
“The rat hybridoma cell line YB2/0 is considered as an alternative for the large-scale production of low fucose IgG [ 9 ].”
BackgroundImproving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC
Natsume, A., Niwa, R., & Satoh, M. (2008) · Drug Design Development and Therapy · doi:10.2147/dddt.s4378 · Cited by 233
Chung, A. W., Crispin, M., Pritchard, L., Robinson, H., Gorny, M. K., Yu, X., Bailey-Kellogg, C., Ackerman, M. E., Scanlan, C., Zolla-Pazner, S., et al. (2014) · AIDS · doi:10.1097/qad.0000000000000444 · Cited by 122
“Additionally, specific galactosylation arm linkages were associated with ADCC activity (a-6-arm G1 was positively associated with enhanced ADCC, whereas a-3-arm G1 did not), independent of the presence of fucose, potentially explaining the conflicting observations from numerous groups on the importance of galactosylat…”
BackgroundTaniguchi, N., & Korekane, H. (2011) · BMB Reports · doi:10.5483/bmbrep.2011.44.12.772 · Cited by 130
“Deletion of the core fucose from IgG1 enhances ADCC activity by up to 50-100 fold (96, 97) and several trials using this anti-”
MethodLiu, W., Wang, H., Yu, J., Liu, Y., Lu, W., Chai, Y., Liu, C., Pan, C. S., Yao, W., & Gao, X. (2016) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2016.05.011 · Cited by 122
de Romeuf, C., Dutertre, C., Garff‐Tavernier, M. L., Fournier, N., Gaucher, C., Glacet, A., Jorieux, S., Bihoreau, N., Behrens, C. K., Béliard, R., et al. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06974.x · Cited by 134
“The increase in ADCC has been related to a high galactose (Kumpel et al, 1994), a low fucose content or a lack of fucose (Shields et al, 2002; Shinkawa et al, 2003; Sibéril et al, 2006), or to the presence of a bisecting-GlcNac (Umana et al, 1999).”
BackgroundFrom planta to pharma with glycosylation in the toolbox
Saint‐Jore‐Dupas, C., Faye, L. J.-Y., & Gomord, V. (2007) · Trends in biotechnology · doi:10.1016/j.tibtech.2007.04.008 · Cited by 137
Antibody Glycosylation and Inflammation
Shade, K.-T., & Anthony, R. M. (2013) · Antibodies · doi:10.3390/antib2030392 · Cited by 143
“Conversely, the highly fucosylated IgG1 fraction showed reduced ADCC [39].”
BackgroundRole of Fc Core Fucosylation in the Effector Function of IgG1 Antibodies
Golay, J., Andrea, A. E., & Cattaneo, I. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.929895 · Cited by 141
Hiatt, A., Bohorova, N., Bohorov, O., Goodman, C., Kim, D., Pauly, M. H., Velasco, J., Whaley, K. J., Piedra, P. A., Gilbert, B. E., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1402458111 · Cited by 119
“(43) found that the removal of fucose produces a significant enhancement of cytotoxic potency against the Raji CD20-overexpressing human B lymphoma cell line.”
BackgroundRegulated Glycosylation Patterns of IgG during Alloimmune Responses against Human Platelet Antigens
Wuhrer, M., Porcelijn, L., Kapur, R., Koeleman, C. A. M., Deelder, A. M., de Haas, M., & Vidarsson, G. (2009) · Journal of Proteome Research · doi:10.1021/pr800651j · Cited by 119
Multi-level glyco-engineering techniques to generate IgG with defined Fc-glycans
Dekkers, G., Plomp, R., Koeleman, C. A. M., Visser, R., von Horsten, H. H., Sandig, V., Rispens, T., Wuhrer, M., & Vidarsson, G. (2016) · Scientific Reports · doi:10.1038/srep36964 · Cited by 118
“It has been known for several years that the absence of IgG-Fc core fucose vastly increases binding to Fc γ RIII 21,22 , a finding increasingly being used to improve the efficacy of therapeutic antibodies 23–25 .”
Shibata-Koyama, M., Iida, S., Okazaki, A., Mori, K., Kitajima-Miyama, K., Saitou, S., Kakita, S., Kanda, Y., Shitara, K., Kato, K., et al. (2008) · Glycobiology · doi:10.1093/glycob/cwn110 · Cited by 118
“…Fc oligosaccharides dramatically enhances the effector functions of ADCC via improved FcγRIIIa binding both in vitro and in vivo (Shields et al. 2002; Shinkawa et al. 2003; Niwa, Hatanaka, et al. 2004; Niwa, Shoji-Hosaka, et al. 2004; Yamane-Ohnuki et al. 2004; Niwa et al. 2005; Iida et al. 2006;…”
BackgroundSelf-citationA plant-derived human monoclonal antibody induces an anti-carbohydrate immune response in rabbits
Jin, C., Altmann, F., Strasser, R., Mach, L., Schähs, M., Kunert, R., Rademacher, T., Glössl, J., & Steinkellner, H. (2007) · Glycobiology · doi:10.1093/glycob/cwm137 · Cited by 134
N-Glycosylation of Plant-produced Recombinant Proteins
Bosch, D., Castilho, A., Loos, A., Schots, A., & Steinkellner, H. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319310006 · Cited by 121
Lin, W., Voskens, C. J., Zhang, X., Schindler, D. G., Wood, A., Burch, E., Wei, Y., Chen, L., Tian, G., Tamada, K., et al. (2008) · Blood · doi:10.1182/blood-2007-11-122465 · Cited by 116
“It is reported that the addition of bisecting GlcNAc enhances ADCC much less efficiently than the presence or absence of fucose.(27) Our observation that, regardless the higher GlcNAc content, CTM is less efficient in inducing CD137, phenotypic”
BackgroundShibata‐Koyama, M., Iida, S., Misaka, H., Mori, K., Yano, K., Shitara, K., & Satoh, M. (2009) · Experimental Hematology · doi:10.1016/j.exphem.2008.11.006 · Cited by 123
“ADCC is greatly influenced by the Fc oligosaccharide structures of therapeutic antibodies [6,7], and removal of the core fucose from Fc oligosaccharides greatly enhances the effector functions of ADCC via improved FcgRIIIa binding [8,9].”
BackgroundSelf-citationAnti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice
Zeng, Y., Fest, S., Kunert, R., Katinger, H. W. D., Pistoia, V., Michon, J. M., Lewis, G., Ladenstein, R. L., & Lode, H. N. (2005) · Molecular Immunology · doi:10.1016/j.molimm.2004.12.018 · Cited by 121
Comparison of cell lines for stable production of fucose‐negative antibodies with enhanced ADCC
Kanda, Y., Yamane‐Ohnuki, N., Sakai, N., Yamano, K., Nakano, R., Inoue, M., Misaka, H., Iida, S., Wakitani, M., Konno, Y., et al. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.20880 · Cited by 115
“(Kamoda et al., 2004; Shinkawa et al., 2003), which means that ADCC activity is far from optimal.”
BackgroundMethodResultInfluentialSelf-citationThe protein science of biosimilars
Kuhlmann, M. K., & Covic, A. C. (2006) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfl474 · Cited by 114
“The ADCC of two types of mAb (one of which was rituximab) was found to vary inversely according to the mAb’s glycosylation state [4].”
BackgroundDecoding sugar functions by identifying target glycoproteins
Taniguchi, N., Miyoshi, E., Jianguo, G., Honke, K., & Matsumoto, A. (2006) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2006.08.011 · Cited by 115
Transgenic silkworms that weave recombinant proteins into silk cocoons
Tomita, M. (2010) · Biotechnology Letters · doi:10.1007/s10529-010-0498-z · Cited by 113
“The absence of a-1,6-fucose enhances the activity of the antibodydependent cellular cytotoxicity of IgG (Shields et al. 2002; Shinkawa et al. 2003).”
BackgroundDiversification of IgG effector functions
Bournazos, S., & Ravetch, J. V. (2017) · International Immunology · doi:10.1093/intimm/dxx025 · Cited by 112
Boeggeman, E. E., Ramakrishnan, B., Pasek, M., Manzoni, M., Puri, A., Loomis, K. H., Waybright, T. J., & Qasba, P. K. (2009) · Bioconjugate Chemistry · doi:10.1021/bc900103p · Cited by 114
“However, the use of rat hybridoma YB2/0 cells has permitted the production of mAbs that lack fucose in the conserved core oligosaccharide increasing the ADCC activity of the IgG, allowing the antibody to be effective at lower doses (10).”
BackgroundTang, F., Yang, Y., Tang, Y., Tang, S., Yang, L., Sun, B., Jiang, B., Dong, J., Liu, H., Huang, M., et al. (2016) · Organic & Biomolecular Chemistry · doi:10.1039/c6ob01751g · Cited by 116
FcγRIIIb Restricts Antibody-Dependent Destruction of Cancer Cells by Human Neutrophils
Treffers, L. W., van Houdt, M., Bruggeman, C. W., Heineke, M. H., Zhao, X. W., van der Heijden, J., Nagelkerke, S. Q., Verkuijlen, P., Geissler, J., Lissenberg‐Thunnissen, S. N., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03124 · Cited by 135
Kamoda, S., Ishikawa, R., & Kakehi, K. (2006) · Journal of Chromatography A · doi:10.1016/j.chroma.2006.08.028 · Cited by 115
Tang, F., Wang, L., & Huang, W. (2017) · Nature Protocols · doi:10.1038/nprot.2017.058 · Cited by 116
Novel Concepts of Altered Immunoglobulin G Galactosylation in Autoimmune Diseases
Dekkers, G., Rispens, T., & Vidarsson, G. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00553 · Cited by 125
“It has been known for over a decade that afucosylation increases affinity of IgG1 to FcγRIIIa and FcγRIIIb (49, 50), and later confirmed for other IgG subclasses (51, 52).”
BackgroundInfluentialYoungblood, B. A., Brock, E. C., Leung, J., Falahati, R., Bryce, P. J., Bright, J., Williams, J., Shultz, L. D., Greiner, D. L., Brehm, M. A., et al. (2019) · International Archives of Allergy and Immunology · doi:10.1159/000501637 · Cited by 111
CCR4 as a Therapeutic Target for Cancer Immunotherapy
Yoshie, O. (2021) · Cancers · doi:10.3390/cancers13215542 · Cited by 116
“The original observation was that monoclonal IgG1 antibodies with low fucose contents had more than a 50‐fold higher ADCC activity than the high fucose content counterparts using human peripheral blood mononuclear cells (PBMCs) as effector cells [143].”
BackgroundGlycosylation of therapeutic proteins in different production systems
Werner, R. G., Kopp, K., & Schlueter, M. (2007) · Acta Paediatrica · doi:10.1111/j.1651-2227.2007.00199.x · Cited by 134
“This polymorphism results in different binding affinities; hence, monoclonal antibodies have to be selected for high affinity for both variants (29,30).”
BackgroundEffects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys
Leabman, M. K., Meng, Y. G., Kelley, R. F., DeForge, L. E., Cowan, K. J., & Iyer, S. (2013) · mAbs · doi:10.4161/mabs.26436 · Cited by 110
“While the absence of the glycan at N297 abolishes binding to FcγRs and antibody effector functions, specific glycosylation patterns at N297, notably absence of the core fucose (afucosylation), can increase binding affinity to FcγRIIIA and, thereby, increase effector functions like ADCC activity.(7,8) In cases where an…”
BackgroundSuzuki, E., Niwa, R., Saji, S., Muta, M., Hirose, M., Iida, S., Shiotsu, Y., Satoh, M., Shitara, K., Kondo, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1335 · Cited by 110
Self-citationA close look at human IgG sialylation and subclass distribution after lectin fractionation
Stadlmann, J., Weber, A., Pabst, M., Anderle, H., Kunert, R., J. Ehrlich, H., Peter Schwarz, H., & Altmann, F. (2009) · PROTEOMICS · doi:10.1002/pmic.200800931 · Cited by 109
“Non-fucosylated IgGs have a greatly enhanced antibody-dependent cellular cytotoxicity and therefore may present as a more effective new-generation antibody variant for therapeutics [2, 3].”
BackgroundKodar, K., Stadlmann, J., Klaamas, K., Sergeyev, B., & Kurtenkov, O. A. (2011) · Glycoconjugate Journal · doi:10.1007/s10719-011-9364-z · Cited by 119
Engineering therapeutic monoclonal antibodies
Liu, X., Pop, L. M., & Vitetta, E. S. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00601.x · Cited by 130
Impact of autoantibody glycosylation in autoimmune diseases
Goulabchand, R., Vincent, T., Batteux, F., Eliaou, J., & Guilpain, P. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.02.005 · Cited by 120
Mahan, A. E., Tedesco, J., Dionne, K., Baruah, K., Cheng, H. D., De Jager, P. L., Barouch, D. H., Suscovich, T., Ackerman, M., Crispin, M., et al. (2015) · Journal of Immunological Methods · doi:10.1016/j.jim.2014.12.004 · Cited by 108
“Studies of therapeutic monoclonal antibodies have clearly demonstrated the critical nature of the antibody glycan; ADCC activity is significantly increased in monoclonal therapeutic antibodies that lack fucose (Shields et al., 2002; Shinkawa et al., 2003; Shoji-Hosaka et al., 2006) or contain a bisecting Nacetylglucos…”
BackgroundInfluentialCharacterization of Humanized Antibodies Secreted by Aspergillus niger
Ward, M., Lin, C., Victoria, D. C., Fox, B. P., Fox, J. A., Wong, D. L., Meerman, H. J., Pucci, J. P., Fong, R. B., Heng, M. H., et al. (2004) · Applied and Environmental Microbiology · doi:10.1128/aem.70.5.2567-2576.2004 · Cited by 108
“In addition, recent studies have shown that the removal of fucose in attached carbohydrates results in an increase in the ADCC activity of human IgG1 antibodies (21, 22).”
BackgroundHow does mild hypothermia affect monoclonal antibody glycosylation?
Sou, S. N., Sellick, C., Lee, K., Mason, A., Kyriakopoulos, S., Polizzi, K. M., & Kontoravdi, C. (2015) · Biotechnology and Bioengineering · doi:10.1002/bit.25524 · Cited by 107
“…the absence of core-fucosylation results in an increase in Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) activity by approximately 50-fold [Shinkawa et al., 2003], while terminal galactosylation increases ComplementDependent Cytotoxicity (CDC) activity of IgG molecules through higher…”
BackgroundSun, B., Srinivasan, B., & Huang, X. (2008) · Chemistry - A European Journal · doi:10.1002/chem.200800757 · Cited by 108
Production of α2,6-sialylated IgG1 in CHO cells
Raymond, C., Robotham, A., Spearman, M., Butler, M., Kelly, J., & Durocher, Y. (2015) · mAbs · doi:10.1080/19420862.2015.1029215 · Cited by 106
Kobata, A. (2007) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2007.06.012 · Cited by 108
High-Throughput Glycomic Methods
Trbojević‐Akmačić, I., Lageveen‐Kammeijer, G. S. M., Heijs, B., Pribić, T., Deriš, H., Wuhrer, M., & Lauc, G. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c01031 · Cited by 120
Transient expression and purification of chimeric heavy chain antibodies
Zhang, J., Liu, X., Bell, A., To, R., Baral, T. N., Azizi, A., Li, J., Cass, B., & Durocher, Y. (2008) · Protein Expression and Purification · doi:10.1016/j.pep.2008.10.011 · Cited by 110
Current achievements in the production of complex biopharmaceuticals with moss bioreactors
Decker, E. L., & Reski, R. (2007) · Bioprocess and Biosystems Engineering · doi:10.1007/s00449-007-0151-y · Cited by 121
“Appropriate glycosylation may be important for activity, stability or immunogenicity of a protein [6, 15] or may influence the affinity and effectiveness of certain antibodies (antibody-dependent cellular cytotoxicity—ADCC) [16, 17].”
BackgroundSilence, K., Dreier, T., Moshir, M., Ulrichts, P., Gabriëls, S., Saunders, M. J., Wajant, H., Brouckaert, P., Huyghe, L., Hauwermeiren, T. V., et al. (2013) · mAbs · doi:10.4161/mabs.27398 · Cited by 103
“In contrast to antibody-drug conjugates, which are designed to deliver a cytotoxic chemotherapy payload and require internalization for optimal function,(28) ARGX110 has been modified using POTELLIGENT technology to augment the immune system activation that is induced by the Fc portion of the antibody.(17) Hence ARGX-…”
BackgroundMethodInfluentialvon Horsten, H. H., Ogorek, C., Blanchard, V., Demmler, C., Giese, C., Winkler, K., Kaup, M., Berger, M., Jordan, I., & Sandig, V. (2010) · Glycobiology · doi:10.1093/glycob/cwq109 · Cited by 103
Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab
Liu, J., Eris, T., Li, C., Cao, S., & Kuhns, S. T. (2016) · BioDrugs · doi:10.1007/s40259-016-0184-3 · Cited by 113
Engaging innate immunity in HIV-1 cure strategies
Nathan L. Board, Moskovljevic, M., Wu, F., Siliciano, R. F., & Siliciano, J. D. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00649-1 · Cited by 107
Putnam, W. S., Prabhu, S., Zheng, Y., Subramanyam, M., & Wang, Y. (2010) · Trends in biotechnology · doi:10.1016/j.tibtech.2010.07.001 · Cited by 108
Plasma N-Glycan Signatures Are Associated With Features of Inflammatory Bowel Diseases
Clerc, F., Novokmet, M., Dotz, V., Reiding, K. R., de Haan, N., Lageveen‐Kammeijer, G. S. M., Dalebout, H., Bladergroen, M. R., Vukovic, F., Rapp, E., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.05.030 · Cited by 108
Development and validation of an antibody-dependent cell-mediated cytotoxicity-reporter gene assay
Parekh, B. S., Berger, E., Sibley, S., Cahya, S., Liqun, X., LaCerte, M. A., Vaillancourt, P., Wooden, S. K., & Gately, D. P. (2012) · mAbs · doi:10.4161/mabs.19873 · Cited by 113
Non-fucosylated therapeutic antibodies: the next generation of therapeutic antibodies
Mori, K., Iida, S., Yamane‐Ohnuki, N., Kanda, Y., Kuni‐Kamochi, R., Nakano, R., Imai, H., Okazaki, A., Shinkawa, T., Natsume, A., et al. (2007) · Cytotechnology · doi:10.1007/s10616-007-9103-2 · Cited by 111
“Among these efforts, the modification of N-linked Fc oligosaccharides, especially core-fucose removal, has been of note as a key of next generation therapeutic antibodies with improved efficacy (Shields et al. 2002; Shinkawa et al. 2003; Yamane-Ohnuki et al. 2004; Mori et al. 2004; Okazaki et al. 2004; Niwa et al. 200…”
BackgroundSelf-citationMurer, P., & Neri, D. (2019) · New Biotechnology · doi:10.1016/j.nbt.2019.04.002 · Cited by 108
“Changing the amino acid composition, the isotype or the glycans of the Fc portion may reduce these off target effects [20, 21].”
BackgroundKaur, H. (2021) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2020.1869684 · Cited by 109
Genetic glycoengineering in mammalian cells
Narimatsu, Y., Büll, C., Chen, Y., Wandall, H. H., Yang, Z., & Clausen, H. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100448 · Cited by 107
Glycobiology of rheumatic diseases
Kissel, T., Toes, R. E. M., Huizinga, T. W. J., & Wuhrer, M. (2022) · Nature Reviews Rheumatology · doi:10.1038/s41584-022-00867-4 · Cited by 119
Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy
Kellner, C., Otte, A., Cappuzzello, E., Klausz, K., & Peipp, M. (2017) · Transfusion Medicine and Hemotherapy · doi:10.1159/000479980 · Cited by 118
The recognition of glycans by protein receptors. Insights from NMR spectroscopy
Ardá, A., & Jiménez‐Barbero, J. (2018) · Chemical Communications · doi:10.1039/c8cc01444b · Cited by 105
Nimmerjahn, F., Vidarsson, G., & Cragg, M. S. (2023) · Nature Immunology · doi:10.1038/s41590-023-01544-8 · Cited by 110
André, S., Kožár, T., Schuberth, R., Unverzagt, C., Kojima, S., & Gabius, H.-J. (2007) · Biochemistry · doi:10.1021/bi7000467 · Cited by 99
Analytical comparability study of recombinant monoclonal antibody therapeutics
Ambrogelly, A., Gozo, S., Katiyar, A., Dellatore, S. M., Kune, Y., Bhat, R., Sun, J., Li, N., Wang, D., Nowak, C., et al. (2018) · mAbs · doi:10.1080/19420862.2018.1438797 · Cited by 106
Wei, Y., Li, C., Huang, W., Li, B., Strome, S. E., & Wang, L. (2008) · Biochemistry · doi:10.1021/bi800874y · Cited by 109
“Many studies have shown that not only is ADCC dependent on the presence of the Fc glycosylation, but the efficiency of cellmediated killing is sensitive to the precise structure of the glycans attached at the Fc domain (12-18,26,27).”
BackgroundGalbraith, D. J., Tait, A. S., Racher, A. J., Birch, J. R., & James, D. C. (2006) · Biotechnology Progress · doi:10.1021/bp050339v · Cited by 97
Chemokine Receptor-Specific Antibodies in Cancer Immunotherapy: Achievements and Challenges
Vela, M., Aris, M., Llorente, M., García‐Sanz, J. A., & Kremer, L. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00012 · Cited by 114
“Defucosylation increases Fc-binding to the Fcγ receptors expressed on cytotoxic cells, activating them for tumor cell killing (245).”
BackgroundIida, S., Kuni-Kamochi, R., Mori, K., Misaka, H., Inoue, M., Okazaki, A., Shitara, K., & Satoh, M. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-58 · Cited by 96
“Monosaccharide composition of IgG1 was characterized by modified high-performance anion exchange chromatography (HPAEC) analysis as previously described [28].”
MethodSelf-citationKemna, M. J., Plomp, R., van Paassen, P., Koeleman, C. A. M., Jansen, B. C., Damoiseaux, J. G. M. C., Tervaert, J. W. C., & Wuhrer, M. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.01.033 · Cited by 106
“…the effect of a bisecting GlcNAc on IgG effector functions is minor compared to that of the other glycosylation features, it has been reported that bisection can enhance antibody-dependent cellular cytotoxicity (ADCC) through increased FcγRIIIa affinity (Davies et al., 2001; Shinkawa et al., 2003).”
BackgroundSialylation as an Important Regulator of Antibody Function
Vattepu, R., Sneed, S. L., & Anthony, R. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.818736 · Cited by 118
“However, the addition of biGlcNAc inhibits the addition of a core fucose residue due to steric hinderance, and increased ADCC is also attributed to the inhibition of fucose attachment (83).”
BackgroundBiolayer interferometry and its applications in drug discovery and development
Jug, A., Bratkovič, T., & Ilaš, J. (2024) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2024.117741 · Cited by 107
HOLLAND, M., Hewins, P., Goodall, M. D., Adu, D., Jefferis, R., & Savage, C. O. S. (2004) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2004.02566.x · Cited by 97
Kurogochi, M., Mori, M., Osumi, K., Tojino, M., Sugawara, S.-I., Takashima, S., Hirose, Y., Tsukimura, W., Mizuno, M., Amano, J., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0132848 · Cited by 96
“Glycoproteins from transgenic cocoon extracts consist of non-fucosylated N-glycan [26] and are suitable for the preparation of mAbs without a core fucose, which will have higher ADCC activity than that of conventional mAbs with a core fucose [15, 16, 56, 57, 58, 59]; thus, this was chosen as the starting material.”
BackgroundWang, Y., Fukuda, T., Isaji, T., Lu, J., Im, S., Hang, Q., Gu, W., Hou, S., Ohtsubo, K., & Gu, J. (2015) · The FASEB Journal · doi:10.1096/fj.15-270710 · Cited by 100
“These studies clearly explained why the lack of a core fucose on IgG could greatly enhance antibody-dependent cellular cytotoxicity (39, 40).”
BackgroundProduction of a recombinant mouse monoclonal antibody in transgenic silkworm cocoons
Iizuka, M., Ogawa, S., Takeuchi, A., Nakakita, S., Kubo, Y., Miyawaki, Y., Hirabayashi, J., & Tomita, M. (2009) · FEBS Journal · doi:10.1111/j.1742-4658.2009.07262.x · Cited by 95
Complement and cellular cytotoxicity in antibody therapy of cancer
Wang, S., & Weiner, G. J. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.6.759 · Cited by 110
“Increasing the bisected complex oligosaccharides on the Fc region of mAbs and removing fucose on the IgG N-linked oligosaccharide chain has been shown to enhance its ADCC activity [63,64] .”
BackgroundAntibody glycoengineering strategies in mammalian cells
Wang, Q., Chung, C., Chough, S., & Betenbaugh, M. J. (2018) · Biotechnology and Bioengineering · doi:10.1002/bit.26567 · Cited by 95
“…have shown that the core-fucose residue of the CH2-associated N-linked oligosaccharides plays a critical role in regulating the magnitude of antibody effector function ADCC (Iida et al., 2006; Satoh, Iida, & Shitara, 2006; Shields et al., 2002; Shinkawa et al., 2003; Yamane-Ohnuki et al., 2004).”
BackgroundEngineering Cells for Cell Culture Bioprocessing – Physiological Fundamentals
Seth, G., Hossler, P., Yee, J. C., & Hu, W. (2006) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_017 · Cited by 113
FcRn, but not FcγRs, drives maternal-fetal transplacental transport of human IgG antibodies
Borghi, S., Bournazos, S., Thulin, N. K., Li, C., Gajewski, A., Sherwood, R., Zhang, S., Harris, E., Jagannathan, P., Wang, L., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2004325117 · Cited by 107
de Kreutzenberg, S. V., Ceolotto, G., Cattelan, A. M., Pagnin, E., Mazzucato, M., Garagnani, P., Borelli, V., Bacalini, M. G., Franceschi, C., Fadini, G. P., et al. (2015) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2015.03.007 · Cited by 99
Kao, D., Danzer, H., Collin, M., Groß, A., Eichler, J., Štambuk, J., Lauc, G., Lux, A., & Nimmerjahn, F. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.11.027 · Cited by 93
“2376 Cell Reports 13, 2376–2385, December 22, 2015 a2015 The Au ing in enhanced cytotoxic activity (Nimmerjahn and Ravetch, 2005; Shinkawa et al., 2003).”
BackgroundThe role of differential IgG glycosylation in the interaction of antibodies with FcγRs in vivo
Anthony, R. M., & Nimmerjahn, F. (2011) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e328342538f · Cited by 93
A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens
Chang, A. Y., Dao, T., Gejman, R. S., Jarvis, C. A., Scott, A., Dubrovsky, L., Mathias, M. D., Korontsvit, T., Zakhaleva, V., Curcio, M., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92335 · Cited by 92
Bush, D. R., Zang, L., Belov, A. M., Ivanov, A. R., & Karger, B. L. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.5b03218 · Cited by 92
Hutmacher, C., & Neri, D. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.09.002 · Cited by 99
Fukuda, T., Hashimoto, H., Okayasu, N., Kameyama, A., Onogi, H., Nakagawasai, O., Nakazawa, T., Kurosawa, T., Hao, Y., Isaji, T., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.172536 · Cited by 98
FcγR: The key to optimize therapeutic antibodies?
Sibéril, S., Dutertre, C., Fridman, W. H., & Teillaud, J. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.12.003 · Cited by 103
van Berkel, P. H. C., Gerritsen, J., Perdok, G., Valbjørn, J., Vink, T., van de Winkel, J. G. J., & Parren, P. W. H. I. (2009) · Biotechnology Progress · doi:10.1002/btpr.92 · Cited by 92
“Galactosylation may improve complement dependent cytotoxicity,9–11 whereas the absence of a core-fucose on the reducing N-acetylglucosamine strongly enhances ADCC.7,8,34 Hence, if sufficient high-expressing cell lines are available in the final stage of selection, one should preferably select the cell line with the hi…”
BackgroundUse of Transgenic Animals in Biotechnology: Prospects and Problems
Maksimenko, O. G., Deykin, A. V., Khodarovich, Y. M., & Georgiev, P. G. (2013) · Acta Naturae · doi:10.32607/20758251-2013-5-1-33-46 · Cited by 112
Schuster, M., Jost, W. H., Mudde, G. C., Wiederkum, S., Schwager, C., Janzek, E., Altmann, F., Stadlmann, J., Stemmer, C., & Gorr, G. (2007) · Biotechnology Journal · doi:10.1002/biot.200600255 · Cited by 92
Metadata
- Authors
- Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., Hanai, N., & Shitara, K.
- Affiliations
- Kyowa Kirin (Japan) (JP)
- Corresponding author
- Shitara, Kenya
- ORCID
- Uchida, Kazuhisa
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-01
- Volume
- 278
- Issue
- 5
- Pages
- 3466-3473
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2084136419
- Cited by
- 1,413
- References
- 33
- Citations by year
- 2026: 37 · 2025: 47 · 2024: 55 · 2023: 45 · 2022: 77 · 2021: 78 · 2020: 87 · 2019: 70 · 2018: 83 · 2017: 77 · 2016: 71 · 2015: 72 · 2014: 78 · 2013: 56 · 2012: 67
- FWCI
- 14.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6498 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Keywords
- antibody-dependent cellular cytotoxicity, fucosylation, bisecting N-acetylglucosamine, galactose, FUT8, alpha-1,6-fucosyltransferase, humanized monoclonal antibody, CHO cell expression, antibody glycosylation, therapeutic antibodies
- MeSH terms
- Acetylglucosamine, Animals, Antibody-Dependent Cell Cytotoxicity, Base Sequence, Carbohydrate Conformation, Carbohydrate Sequence, Cell Line, Chromatography, Affinity, Fucose, Galactose, Cricetinae, Humans, Immunoglobulin G, Molecular Sequence Data, Oligosaccharides, Recombinant Fusion Proteins, Transfection, Polymerase Chain Reaction, CHO Cells, DNA Primers, Lectins, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.